Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07792122 Propranolol Hydrochloride Stress Disorders, Post-Traumatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07792122 clinical trial report covering Propranolol Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07791732 Raludotatug deruxtecan Ovarian Serous Tumor Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07791732 clinical trial report covering Raludotatug deruxtecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07793409 Lunsekimig Pulmonary Disease, Chronic Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07793409 clinical trial report covering Lunsekimig, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07794579 Orforglipron Prediabetic State Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07794579 clinical trial report covering Orforglipron, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07792096 Dolutegravir Sodium HIV Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07792096 clinical trial report covering Dolutegravir Sodium, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07789483 NI-006 Transthyretin Amyloid Cardiomyopathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07789483 clinical trial report covering NI-006, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07793422 Etentamig Immunoglobulin Light-Chain Amyloidosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07793422 clinical trial report covering Etentamig, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07795164 Pemvidutide Metabolic Dysfunction Associated Steatohepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07795164 clinical trial report covering Pemvidutide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07795268 177Lu-NY108 Metastatic castration-resistant prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07795268 clinical trial report covering 177Lu-NY108, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07795346 ATG-022 CLDN18.2 positive Gastroesophageal junction adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07795346 clinical trial report covering ATG-022, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07794397 Poterepatide Sleep Apnea, Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07794397 clinical trial report covering Poterepatide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07794761 Berobenatide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07794761 clinical trial report covering Berobenatide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.